Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Actinogen Medical ( (AU:ACW) ).
Actinogen Medical Limited has applied for quotation on the ASX of 27,566 new fully paid ordinary shares, issued following the exercise or conversion of options or other convertible securities. While a relatively small allotment, the additional quoted shares modestly expand the company’s equity base and reflect ongoing capital management activity as Actinogen advances its operations and development programs, with implications for existing shareholders’ dilution and market liquidity.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited is an Australian biotechnology company listed on the ASX under the code ACW, operating in the medical and life sciences sector. The company focuses on developing pharmaceutical and therapeutic products, with a primary emphasis typical of biotechs on clinical-stage research and development to address unmet medical needs.
Average Trading Volume: 5,459,115
Technical Sentiment Signal: Buy
Current Market Cap: A$159.6M
Find detailed analytics on ACW stock on TipRanks’ Stock Analysis page.